An interventional study of Vitamin C in Corona Virus Infection, sponsored by University of Lahore. Completed at 1 site in Pakistan. Per ClinicalTrials.gov, last updated 2022-05-06.
Sponsored by University of Lahore · Not applicable, Interventional, and Treatment
Vitamin C (ascorbic acid) is a water-soluble vitamin having anti-inflammatory, immunomodulatory, anti-oxidative, antithrombotic and antiviral properties. Considering these effects vitamin C should have beneficial impact in patients suffering from sepsis and acute respiratory distress syndrome (ARDS). The current study is designed to assess the beneficial effects of Vitamin C in COVID-19 infected patients.
929 studies on the registry are indexed under Coronavirus Infections; 50 are open to participants now.
This study's enrollment of 278 is above the median of 107 across 541 interventional studies indexed under Coronavirus Infections.
Browse Coronavirus Infections studies →University of Lahore is the lead sponsor of 223 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
critically ill patients admitted in ICU
Exclusion Criteria:
allergic to Vitamin C didnt given the consent
The dose would be 30 grams a day (10 grams TDS) for 3 days with standard treatment
Drug: Vitamin C
Distill water in the same dose with same standard treatment
mega dose is given to the selected critically ill patients
Partial pressure of Oxygen in arterial blood to fraction of inspired Oxygen (P/F ratio)
Time frame: 1 and 4th day
Survival analysis
Time frame: 28 days follow up
Length of Hospital stay
Time frame: Admission to discharge
Need for intubation
number of intubations needed in both groups.
Time frame: 28 days
Inflammatory markers
comparison of the inflammatory markers, CRP, D.Dimer, Procalcitonin, LDH, TLC and hematological variables at day four after the intervention started.
Time frame: before the start of treatment (day 1) and on day 4
APACHE II score
Time frame: before the start of treatment (day 1) and on day 4
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Lahore